UPC sees flurry of pharma suits in January but drug patent disputes remain rare
Shutterstock/Christoph Burgstedt IAM breaks down early trends in drug patent spats, following Boehringer Ingelheim’s assertion against Zentiva at the pan-EU court Register for limited access Register to receive our newsletter and gain limited access to …